Anxiety disorders in Parkinson's disease

References

• ALEXANDER, G.E., DELONG, M.R. & STRICK, P.L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuro-science, 9, 357-381.
   PubMed Web of Science ®Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION (1994). Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, DC: American Psychiatric Press.
   Google Scholar
• ANDERSEN, J., AABRO, E., GULMANN, N., HJELMSTED, A. & PEDERSEN, H.E. (1980). Anti-depressive treatment in Parkinson’s disease. A controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-DOPA. Acta Neurologica Scandinavica, 62, 210-219.
   PubMed Web of Science ®Google Scholar
• BERLAN, M., RASCOL, O., BELIN, J., MOATTI, J., RASCOL, A. & MONTASTRUC, J. (1989).Alpha-2 adrenergic sensitivity in Parkinson’s disease. Clinical Neuropharmacology, 12, 138-144.
   PubMed Web of Science ®Google Scholar
• BERRIOS, G.E., CAMPBELL, C. & POLITYNSKA, B.E. (1995). Autonomic failure, depression and anxiety in Parkinson’s disease. British Journal of Psychiatry, 166, 789-792.
   Google Scholar
• BROWN, R.G. & MACCARTHY, B. (1990). Psychiatric morbidity in patients with Parkinson’s disease. Psychological Medicine, 20, 77-87.
   Google Scholar
• BROWN, R.G., MARSDEN, C.D., QUINN, N. & WYKE, M.A. (1984).Alterations in cognitive performance and affect-arousal state during ¯ uctuations in motor function in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 47, 454-465.
   PubMed Web of Science ®Google Scholar
• CANTELLO, R., GILLI, M., RICCIO, A. & BERGAMASCO, B. (1986). Mood changes associated with `end-of-dose deterioration’ in Parkinson’s disease: a controlled study. Journal of Neurology, Neurosurgery and Psychiatry, 49, 1182-1190.
   PubMed Web of Science ®Google Scholar
• CASH, R., RUBERG, M., RAISMAN, R. & AGID, Y. (1984).Adren-ergic receptors in Parkinson’s disease. Brain Research, 322, 269-275.
   PubMed Web of Science ®Google Scholar
• CASH, R., DENNIS, T., L’HEUREUX, R., RAISMAN, R., JAVOY-AGID, F. & SCATTON, B. (1987). Parkinson’s disease and dementia: norepinephrine and dopamine in locus ceru-leus. Neurology, 37, 42-46.
   PubMed Web of Science ®Google Scholar
• CEDARBAUM, J.M. & AGHAJANIAN, G.K. (1977). Catecho-lamine receptors on locus ceruleus neurons: pharmacological characterization.European Neuropsychop-harmacology, 44, 375-385.
   Google Scholar
• CHOUINARD, G. & SULTAN, S. (1992).A case of Parkinson’s disease exacerbated by ¯ uoxetine.Human Psychopharma-cology, 7, 63-66.
   Web of Science ®Google Scholar
• COOPER, J.A., SAGAR, H.J., DOHERTY, S.M., JORDAN, N., TIDSWELL, P. & SULLIVAN, E.V. (1992).Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. B rain, 115, 1701-1725.
   Google Scholar
• CUMMINGS, J.L. (1992).Depression and Parkinson’s disease: a review. American Journal of Psychiatry, 149, 443-454.
   PubMed Web of Science ®Google Scholar
• DELIS, D.C., DIRENFELD, L., ALEXANDER, M.P. & KAPLAN, E. (1982). Cognitive ¯ uctuations associated with on off phenomenon in Parkinson’s disease.Neurology,32,1049-1052.
   Google Scholar
• DUBOIS, B. & PILLON, B. (1997).Cognitive de cits in Parkinson’s disease. Journal of Neurology, 244, 2-8.
   PubMed Web of Science ®Google Scholar
• ELLRING, H., SEILER, S., PERLETH, B., FRINGS, W., GASSER, T. & OERTEL, W. (1993). Psychosocial aspects of Parkinson’s disease. Neurology, 43(Suppl 6), S41 S44
   Google Scholar
• FETONI, V., SOLIVERI, P., MONZA, D., TESTA, D. & GIROTTI, F. (1999). Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy. Journal of Neurology, Neurosurgery and Psychiatry, 66, 541-544.
   PubMed Web of Science ®Google Scholar
• FLEMINGER, S. (1991). Left-sided Parkinson’s disease is associated with greater anxiety and depression. Psychological Medicine, 21, 629-638.
   PubMed Web of Science ®Google Scholar
• GIBB, W.R. & LEES, A.J. (1988).The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 51, 745-752.
   PubMed Web of Science ®Google Scholar
• GOETZ, C.G. & STEBBINS, G.T. (1993). Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology, 43, 2227-2229.
   PubMed Web of Science ®Google Scholar
• GOETZ, C.G., TANNER, C.M. & KLAWANS, H.L. (1984). Bupropion in Parkinson’s disease. Neurology, 34, 1092-1094.
   PubMed Web of Science ®Google Scholar
• GOLDMAN, W.P., BATY, J.D., BUCKLES, V.D., SAHRMANN, S. & MORRIS, J.C. (1998).Cognitive and motor functioning in Parkinson disease. Archives of Neurology, 55, 674-680.
   PubMedGoogle Scholar
• GONERA, E.G., VAN’T HOF, M., BERGER, J.C., VANWEEL, C. & HORSTINK, M.W. (1997). Symptoms and duration of the prodromal phase in Parkinson’s disease. Movement Disorders, 12, 871-876.
   PubMed Web of Science ®Google Scholar
• GOTHAM, A.M., BROWN, R.G. & MARSDEN, C.D. (1988). `Frontal’ cognitive function in patients with Parkinson’s disease `on’ and `off’ levodopa. B rain, 111, 299-321.
   Google Scholar
• HARTMANN, J., KUNIG, G. & RIEDERER, P. (1993). Involvement of transmitter systems in neuropsychiatric diseases. Acta Neurologica Scandinavica, 87(Suppl 146), 18-21.
   Google Scholar
• HAUSER, R.A. & ZESIEWICZ, T.A. (1997). Sertraline for the treatment of depression in Parkinson’s disease. Movement Disorders, 12, 756-759.
   PubMed Web of Science ®Google Scholar
• HELLER, W. (1993). Neuropsychological mechanisms of individual differences in emotion, personality, and arousal. Neuropsychology, 7, 476-489.
   Google Scholar
• HENDERSON, R., KURLAN, R., KERSUN, J.M. & COMO, P. (1992). Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. Journal of Neuropsychiatry and Clinical Neurosciences, 4, 257-264.
   PubMed Web of Science ®Google Scholar
• HOEHN-SARIC, R. (1998). Generalised anxiety disorder. Guidelines for diagnosis and treatment. CNS Drugs, 9, 85-98.
   Google Scholar
• HUTCHINSON, M. & FAZZINI, E. (1996).Cholinesterase inhibition in Parkinson’s disease [letter]. Journal of Neurology, Neurosurgery and Psychiatry, 61, 324-325.
   PubMed Web of Science ®Google Scholar
• IRUELA, L.M., IBANEZ-ROJO, V., PALANCA, I. & CABALLERO, L. (1992). Anxiety disorders and Parkinson’s disease. American Journal of Psychiatry, 149, 719-720.
   Web of Science ®Google Scholar
• JUNCOS, J.L. (1999). Management of psychotic aspects of Parkinson’s disease. Journal of Clinical Psychiatry, 60, 42-53.
   PubMedGoogle Scholar
• KLAASSEN, T., VERHEY, F.R., SNEIJDERS, G.H., ROZENDAAL, N., DE VET, H.C. & VAN PRAAG, H.M. (1995).Treatment of depression in Parkinson’s disease: a meta-analysis. Journal of Neuropsychiatry and Clinical Neurosciences, 7, 281-286.
   PubMedGoogle Scholar
• KOLLER, W.C. & RUEDA, M.G. (1998).Mechanism of action of dopaminergic agents in Parkinson’s disease. Neurology, 50(Suppl 6), S11 S14.
   Google Scholar
• KURLAN, R., LICHTER, D. & SCHIFFER, R.B. (1989). Panic/ anxiety in Parkinson’s disease: yohimbine challenge. Neurology, 39(Suppl 1), 421.
   Google Scholar
• LAITINEN, L. (1969). Desipramine in treatment of Parkinson’s disease. A placebo-controlled study. Acta Neuro-logica Scandinavica, 45, 109-113.
   PubMed Web of Science ®Google Scholar
• LANG, A.E. & JOHNSON, K. (1987).Akathisia in Parkinson’s disease. Neurology, 37, 477-481.
   PubMed Web of Science ®Google Scholar
• LAUTERBACH, E.C. (1993).The locus ceruleus and anxiety disorders in demented and nondemented familial parkin-sonism. American Journal of Psychiatry, 150, 994.
   Google Scholar
• LAUTERBACH, E.C. & DUVOISIN, R.C. (1992). Anxiety disorders in familial parkinsonism [letter]. American Jour nal of Psychiatr y, 148, 274.
   Google Scholar
• LEVIN, B.E. & KATZEN, H.L. (1995).Early cognitivechanges and nondementing behavioral abnormalities in Parkinson’s disease. Advances in Neurology, 65, 85-95.
   PubMedGoogle Scholar
• LIEBERMAN, A. (1998). Managing the neuropsychiatric symptoms of Parkinson’s disease. Neurology, 50(Suppl 6), S33 S38.
   Google Scholar
• LUDWIG, C.L., WEINBERGER, D.R., BRUNO, G., GILLESPIE, M., BAKKER, K., LEWITT, P.A. & CHASE, T.N. (1986). Buspirone, Parkinson’s disease, and the locus ceruleus. Clinical Neuropharmacology, 9, 373-378.
   PubMed Web of Science ®Google Scholar
• MACMAHON, D.G. (1999).Parkinson’s disease nurse special-ists.An important role in disease management.Neurology, 52(Suppl 3), S21 S25.
   Google Scholar
• MARICLE, R.A., NUTT, J.G. & CARTER, J.H. (1995a). Mood and anxiety ¯ uctuation in Parkinson’s disease associated with levodopa infusion: preliminary ndings. Movement Disorders, 10, 329-332.
   Google Scholar
• MARICLE, R.A., NUTT, J.G., VALENTINE, R.J. & CARTER, J.H. (1995b). Dose-response relationship of levodopa with mood and anxiety in ¯ uctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology, 45, 1757-1760.
   Google Scholar
• MARSH, L & CASPER, R.C. (1998). Gender differences in brain morphology and in psychiatric disorders. In: R.C. CASPER. (Ed.), Women’s health: hormones, emotions, and behavior (pp. 53-82). Cambridge: Cambridge University Press.
   Google Scholar
• MARSH, G.G. & MARKHAM, C.H. (1973). Does levodopa alter depression and psychopathology in Parkinsonism patients? Journal of Neurology, Neurosurgery and Psychiatr y, 36, 925-935.
   PubMedGoogle Scholar
• MARSH, L., VAUGHAN, C., SCHRETLEN, D., BRANDT, J. & MANDIR, A.S. (2000). Psychomotor aspects of mood disorders in Parkinson’s disease. Biological Psychiatry, 47, 165S 165S.
   Google Scholar
• MARSH, L., SOLVASSON, B., CAHN, D.A., SHEAR, P.K., TEITEL-BAUM, J., WASSERSTEIN, P., HEIT, G., SILVERBERG, G.D. & SULLIVAN, E.V. (1997). Psychiatric outcome after palli-dotomy for Parkinson’s disease. Biological Psychiatry, 41, 107S.
   Google Scholar
• MASTERMAN, D., DESALLES, A., BALOH, R.W., FRYSINGER, R., FOTI, D., BEHNKE, E., CABATAN-AWANG, C., HOETZEL, A., INTEMANN, P.M., FAIRBANKS, L. & BRONSTEIN, J.M. (1998). Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson disease. Archives of Neurology, 55, 1201-1208.
   PubMedGoogle Scholar
• MAYBERG, H.S. (1994). Frontal lobe dysfunction in secondary depression. Journal of Neuropsychiatry and Clinical Neurosciences, 6, 428-442.
   PubMed Web of Science ®Google Scholar
• MAYBERG, H.S. & SOLOMON, D.H. (1995). Depression in Parkinson’s disease:a biochemical and organic viewpoint. Advances in Neurology, 65, 49-60.
   Google Scholar
• MAYEUX, R., STERN, Y., ROSEN, J. & LEVENTHAL, J. (1981). Depression, intellectual impairment, and Parkinson disease. Neurology, 31, 645-650.
   PubMed Web of Science ®Google Scholar
• MCCANCE-KATZ, E.F., MAREK, K.L. & PRICE, L.H. (1992). Serotonergic dysfunction in depression associated with Parkinson’s disease. Neurology, 42, 1813-1814.
   PubMed Web of Science ®Google Scholar
• MENZA, M.A. & ROSEN, R.C. (1995). Sleep in Parkinson’s disease. The role of depression and anxiety. Psychoso-matics, 36, 262-266.
   PubMed Web of Science ®Google Scholar
• MENZA, M.A., ROBERTSON-HOFFMAN, D.E. & BONAPACE, A.S. (1993).Parkinson’s disease and anxiety: comorbidity with depression. Biological Psychiatry, 34, 465-470.
   PubMed Web of Science ®Google Scholar
• MENZA, M.A., FORMAN, N.E., GOLDSTEIN, H.S. & GOLBE, L.I. (1990). Parkinson’s disease, personality, and dopamine. Journal of Neuropsychiatry and Clinical Neuro-sciences, 2, 282-287.
   PubMedGoogle Scholar
• MOHR, E., MENDIS, T. & GRIMES, J.D. (1995).Late cognitive changes in Parkinson’s disease with an emphasis on dementia. Advances in Neurology, 65, 97-113.
   Google Scholar
• MOHR, E., LITVAN, I., WILLIAMS, J., FEDIO, P. & CHASE, T.N. (1990). Selective de cits in Alzheimer and parkinsonian dementia: visuospatial function. The Canadian Jour nal of Neurological Sciences, 17, 292-297.
   PubMed Web of Science ®Google Scholar
• NAUSIEDA, P.A. (1985). Sinemet `abusers’. Clinical Neurop-harmacology, 8, 318-327.
   Google Scholar
• NISSENBAUM, H., QUINN, N.P., BROWN, R.G., TOONE, B., GOTHAM, A.M. & MARSDEN, C.D. (1987). Mood swings associated with the `on off’ phenomenon in Parkinson’s disease. Psychological Medicine, 17, 899-904.
   PubMed Web of Science ®Google Scholar
• NUTT, D. (1997).Management of patients with depression associated with anxiety symptoms. Journal of Clinical Psychiatry, 58(Suppl 8), 11-16.
   Google Scholar
• OLANOW, C.W. & KOLLER, W.C. (1998).An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Neurology, 50(Suppl 3), S1 S57
   Google Scholar
• PARENT, A. & HAZRATI, L.N. (1995).Functional anatomy of the basal ganglia. I.The cortico-basal ganglia-thalamo-cortical loop. B rain Research Reviews, 20, 91-127.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. New England Journal of Medicine, 340, 757-763.
   PubMed Web of Science ®Google Scholar
• POEWE, W. & LUGINGER, E. (1999). Depression in Parkinson’s disease. Impediments to recognition and treatment options. Neurology, 52(Suppl 3), S2 S6
   Google Scholar
• PRICHARD, J.S., SCHWAB, R.S. & TILLMANN, W.A. (1951).The effects of stress and the results of medication in different personalities with Parkinson’s disease. Psychosomatic Medicine, 13, 106-111.
   Google Scholar
• QUINN, N.P. (1998).Classi cation of ¯ uctuationsin patients with Parkinson’s disease. Neurology, 51(Suppl 2), S25 S29.
   Google Scholar
• RAJ, B.A., CORVEA, M.H. & DAGON, E.M. (1993).The clinical characteristics of panic disorder in the elderly: a retrospective study. Jour nal of Clinical Psychiatry, 54, 150-155.
   PubMed Web of Science ®Google Scholar
• REGIER, D.A., BOYD, J.H., BURKE, J.D., RAE, D.S., MYERS, J.K., KRAMER, M., ROBINS, L.N., GEORGE, L.K., KARNO, M. & LOCKE, B.Z. (1988). One-month prevalence of mental disorders in the U.S.: based on ve epidemiologic catchment sites. Archives of General Psychiatry, 45, 977-986.
   PubMed Web of Science ®Google Scholar
• RICHARD, I.H., SCHIFFER, R.B. & KURLAN, R. (1996).Anxiety and Parkinson’s disease. Journal of Neuropsychiatry and Clinical Neurosciences, 8, 383-392.
   PubMed Web of Science ®Google Scholar
• RICHARD, I.H., KURLAN, R., TANNER, C., FACTOR, S., HUBBLE, J., SUCHOWERSKY, O. & WATERS, C. (1997). Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study Group. Neurology, 48, 1070-1077.
   PubMed Web of Science ®Google Scholar
• RIORDAN, H.J., FLASHMAN, L.A. & ROBERTS, D.W. (1997). Neurocognitive and psychosocial correlatesof ventropos-terolateral pallidotomy surgery in Parkinson’s disease. Neurosurgical Focus, 2, 1-9.
   Google Scholar
• RUBIN, A.J., KURLAN, R., MILLER, C. & SHOULSON, I. (1986). Atypical depression and Parkinson’s disease. Annals of Neurology, 20, 150.
   Google Scholar
• SAINT-CYR, J.A., TAYLOR, A.E. & NICHOLSON, K. (1995). Behavior and the basal ganglia. Advances in Neurology, 65, 1-28.
   PubMedGoogle Scholar
• SANO, M., STERN, Y., WILLIAMS, J., COTE, L., ROSENSTEIN, R. & MAYEUX, R. (1989). Coexisting dementia and depression in Parkinson’s disease. Archives of Neurology, 46, 1284-1286.
   PubMedGoogle Scholar
• SCHIFFER, R.B., KURLAN, R., RUBIN, A. & BOER, S. (1988). Evidence for atypical depression in Parkinson’s disease. American Journal of Psychiatry, 145, 1020-1022.
   PubMed Web of Science ®Google Scholar
• SHOULSON, I., GLAUBIGER, G. & CHASE, T.N. (1975). On off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkin-sonian patients. Neurology, 25, 1144-1148.
   PubMed Web of Science ®Google Scholar
• SHULMAN, L.M., SINGER, C., BEAN, J.A. & WEINER, W.J. (1996). Internal tremor in patients with Parkinson’s disease. Movement Disorders, 11, 3-7.
   PubMed Web of Science ®Google Scholar
• SIEMERS, E.R., SHEKHAR, A., QUAID, K. & DICKSON, H. (1993). Anxiety and motor performance in Parkinson’s disease. Movement Disorders, 8, 501-506.
   PubMed Web of Science ®Google Scholar
• STARKSTEIN, S.E. & PETRACCA, G. (1999).Parkinson’s disease. In: R.G. ROBINSON & W.R. YATES (Eds), Psychiatric treatment of the medically ill (pp. 443-457). NewYork: Marcel Dekker.
   Google Scholar
• STEIN, M.B., HEUSER, I.J., JUNCOS, J.L. & UHDE, T.W. (1990). Anxiety disorders in patients with Parkinson’s disease. American Journal of Psychiatry, 147, 217-220.
   PubMed Web of Science ®Google Scholar
• SUCHOWERSKY, O. & DE VRIES, J.D. (1990). Interaction of ¯ uoxetine and selegeline.Canadian Journal of Psychiatry, 35, 571-572.
   PubMed Web of Science ®Google Scholar
• THYER, B.A., PARRISH, R.T., CURTIS, G.C., NESSE, R.M. & CAMERON, O.G. (1985).Ages of onset of DSM-III anxiety disorders. Comprehensive Psychiatry, 26, 113-122.
   PubMed Web of Science ®Google Scholar
• TOMER, R., LEVIN, B.E. & WEINER, W.J. (1993). Obsessive-compulsive symptoms and motor asymmetries in Parkinson’s disease. Neuropsychiatry, Neuropsychology & Behavioral Neurology, 6, 26-30.
   Google Scholar
• UHDE, T.W., MURRAY, M.B., VITTONE, B.J., SIEVER, L.J., BOUL-ENGER, J., KLEIN, E. & MELLMAN, T.A. (1989). Behavioral and physiological effects of short-term and long-term administration of clonidine in panic disorder. Archives of General Psychiatry, 46, 170-177.
   PubMedGoogle Scholar
• VAZQUEZ, A., JIMENEZ-JIMENEZ, F.J., GARCIA-RUIZ, P. & GARCIA-URRA, D. (1993). `Panic attacks’ in Parkinson’s disease. A long-term complication of levodopa therapy. Acta Neurologica Scandinavica, 87, 14-18.
   PubMed Web of Science ®Google Scholar
• VILLANEUVE, A., BERLAN, M., LAFONTAN, M., et al. (1985). Platelet alpha-2-adrenoceptors in Parkinson’s disease: decreased number in untreated patients and recovery after treatment. European Journal of Clinical Investigation, 15, 403-407.
   Google Scholar
• WICHMANN, T. & DELONG, M.R. (1996). Functional and pathophysiological models of the basal ganglia. Current Opinion in Neurobiology, 6, 751-758.
   PubMed Web of Science ®Google Scholar
• WICHMANN, T., VITEK, J.L. & DELONG, M.R. (1995). Parkinson’s disease and the basal ganglia:lessons from the laboratory and from neurosurgery.The Neuroscientist,1, 236-244.
   Google Scholar
• WOLTERS, E.C. (1999). Dopaminomimetic psychosis in Parkinson’s disease patients. Neurology, 52(Suppl 3), S10 S13.
   Google Scholar
• ZOLDAN, J., FRIEDBERG, G., WEIZMAN, A. & MELAMED, E. (1996). Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson’s disease. Advances in Neurology, 69, 541-544.
   Google Scholar